<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03606759</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2014/43</org_study_id>
    <nct_id>NCT03606759</nct_id>
  </id_info>
  <brief_title>Evaluation of the Efficacy of the Individually Adjusted Therapy Scale (ATI) on the Addiction Severity</brief_title>
  <acronym>AjusT</acronym>
  <official_title>Evaluation of the Efficacy of the Individually Adjusted Therapy Scale (ATI) on the Addiction Severity of Patients in Treatment for a Substance Use Disorder or a Gambling Disorder. A Multicenter Randomized Controlled Trial (AjusT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The management of the craving is a key element in addiction treatment as the craving is&#xD;
      linked to the probability of relapse. Several cues could induce the craving, some generic&#xD;
      substance-induced cues or addictive behavior-related cues (e.g. gambling-related cues), and&#xD;
      also some more subject-specific cues. The awareness of the craving intensity and its&#xD;
      individual cues for each patient will allow the clinician to tailor a better treatment. The&#xD;
      aim of this study is to evaluate the efficacy of a program based on an Individually Adjusted&#xD;
      Therapy scale added to a treatment as usual for the treatment of addiction.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Addiction is one of the most prevalent psychiatric disorders in general population. In the&#xD;
      DSM-5, substance abuse and substance dependence have been combined into a single substance&#xD;
      use disorder and gambling disorder is now reclassified in the new substance-related and&#xD;
      addictive disorders category. Moreover, a criterion assessing the craving has been added. The&#xD;
      management of craving is an important focus of addiction treatment as craving is often linked&#xD;
      to relapse. Several cues could precipitate the craving. Some of them are substance-related or&#xD;
      gambling-related, some other are more person-specific. Recent studies have revealed that&#xD;
      those &quot;individual cues&quot; are highly predictive of craving and relapse, and suggest that they&#xD;
      are involved in addiction chronicity. The awareness of these cues and the intensity of the&#xD;
      craving are important to tailor a better treatment adapted to the patient's need in order to&#xD;
      prevent relapse. The aim of this study is to evaluate the efficacy of a program that includes&#xD;
      an Individually Adjusted Therapy scale (ATI) to help the clinician to modulate the level of&#xD;
      care regarding of the patient's risk of relapse (based on cues, intensity and frequency of&#xD;
      the craving). The study will consist in a randomized controlled trial comparing 2 groups of&#xD;
      participants that are seeking treatment for substance use disorder (alcohol, opiates,&#xD;
      tobacco, cannabis, cocaine) or gambling disorder in an outpatient addiction clinics in France&#xD;
      (four inclusion sites).&#xD;
&#xD;
      All the participants will be assessed with several questionnaires that evaluate the history&#xD;
      and the severity of addiction.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 31, 2019</start_date>
  <completion_date type="Anticipated">April 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Craving intensity (BILAN-7 jours)</measure>
    <time_frame>3 month</time_frame>
    <description>Craving intensity measured by the difference in craving intensity score at baseline and 3-month follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adjusted Therapy Scale (ATI)</measure>
    <time_frame>Week 1 to Week 11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Addiction Severity Index (ASI)</measure>
    <time_frame>Week 1 to Week 11</time_frame>
    <description>History and the severity of addiction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cues of each participant (QSA)</measure>
    <time_frame>Week 1 to Week 11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mini International Neuropsychiatric Interview (MINI)</measure>
    <time_frame>Week 1 to Week 11</time_frame>
    <description>Psychiatric comorbidities</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">484</enrollment>
  <condition>Addictive Behavior</condition>
  <condition>Substance-Related Disorders</condition>
  <arm_group>
    <arm_group_label>Traitment as usual adjusted on ATI information</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Assessments with a multidisciplinary team (doctors, nurses, psychologists, psychiatrists, social workers) once a week during 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Traitment as usual</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Assessments with a multidisciplinary team (doctors, nurses, psychologists, psychiatrists, social workers) once a week during 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Weekly assessment</intervention_name>
    <description>Weekly assessment during 3 months :&#xD;
Severity of addiction (Addiction Severity Index, ASI) Mini International Neuropsychiatric Interview, MINI Craving intensity (BILAN-7 jours) Individual cues of each participant (QSA) Substance use and gambling (BILAN-7 jours)</description>
    <arm_group_label>Traitment as usual</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Weekly assessment ajusted</intervention_name>
    <description>Weekly assessment during 3 months :&#xD;
Severity of addiction (Addiction Severity Index, ASI) Mini International Neuropsychiatric Interview, MINI Craving intensity (BILAN-7 jours) Individual cues of each participant (QSA) Substance use and gambling (BILAN-7 jours) Individually Adjusted Therapy scale (ATI)</description>
    <arm_group_label>Traitment as usual adjusted on ATI information</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  18 years old or older&#xD;
&#xD;
          -  Meet DSM-5 substance use disorder diagnosis for at least one substance (alcohol,&#xD;
             tobacco, cannabis, opiates, cocaine) or gambling disorder&#xD;
&#xD;
          -  Seek treatment for a substance use disorder or gambling disorder&#xD;
&#xD;
          -  Initiate a treatment for a substance use disorder or gambling disorder at one of the&#xD;
             recruitment site (addiction clinic)&#xD;
&#xD;
          -  Beneficiary of the French Social Security system&#xD;
&#xD;
          -  Give an informed consent to participate&#xD;
&#xD;
             o Exclusion criteria:&#xD;
&#xD;
          -  Severe physical or psychiatric condition that prevents an outpatient treatment&#xD;
&#xD;
          -  Severe physical or psychiatric condition that prevents to complete the assessment&#xD;
&#xD;
          -  Addictive disorder that requires several treatment for several substance use disorder&#xD;
             simultaneously&#xD;
&#xD;
          -  Difficulty to understand and to write French&#xD;
&#xD;
          -  Could not be reachable by phone&#xD;
&#xD;
          -  Participate to another study that prevents to participate to another research&#xD;
&#xD;
          -  Prisoner&#xD;
&#xD;
          -  Person under law protection&#xD;
&#xD;
          -  Person under legal guardianship&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mélina Fatseas</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mélina Fatseas</last_name>
    <phone>05 24 54 90 00</phone>
    <email>melina.fatseas@u-bordeaux.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fuschia Serre</last_name>
    <phone>05 56 56 34 86</phone>
    <email>fuschia.serre@u-bordeaux.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre de Soin d'Accompagnement et de Prévention en Addictologie (CSAPA) BIZIA</name>
      <address>
        <city>Bayonne</city>
        <zip>34 100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Pierre DAULOUEDE</last_name>
      <phone>06 07 34 66 17</phone>
      <email>jean-pierre.daulouede@wanadoo.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bordeaux University Hospital</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fuschia Serre</last_name>
      <phone>05 56 56 34 86</phone>
      <email>fuschia.serre@u-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Charles Perrens</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc AURIACOMBE</last_name>
      <phone>05 56 56 17 38</phone>
      <email>marc.auriacombe@u-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Esquirol</name>
      <address>
        <city>Limoges</city>
        <zip>87 025</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Philippe NUBUKPO</last_name>
      <phone>05 55 43 12 18</phone>
      <email>philippe.nubukpo@9online.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire La Réunion</name>
      <address>
        <city>Saint-Denis</city>
        <zip>97 405</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David METE</last_name>
      <phone>02 62 90 56 01</phone>
      <email>david.mete@chu-reunion.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>July 20, 2018</study_first_submitted>
  <study_first_submitted_qc>July 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2018</study_first_posted>
  <last_update_submitted>December 18, 2019</last_update_submitted>
  <last_update_submitted_qc>December 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Addiction</keyword>
  <keyword>High-risk relapse situation</keyword>
  <keyword>Craving</keyword>
  <keyword>Individual cues</keyword>
  <keyword>Individually tailored treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Substance-Related Disorders</mesh_term>
    <mesh_term>Behavior, Addictive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

